Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000166215 | SCV000216994 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-10-27 | criteria provided, single submitter | clinical testing | The c.1874delT pathogenic mutation, located in coding exon 11 of the PMS2 gene, results from a deletion of one nucleotide at nucleotide position 1874, causing a translational frameshift with a predicted alternate stop codon (p.L625*). This mutation has been detected in multiple individuals with Lynch syndrome-associated cancers and several with tumors showing loss of PMS2 staining on IHC (Goodenberger ML et al. Genet Med, 2016 Jan;18:13-9; Rosty C et al. BMJ Open, 2016 Feb;6:e010293; Pearlman R et al. JAMA Oncol, 2017 Apr;3:464-471; Espenschied CR et al. J Clin Oncol, 2017 Aug;35:2568-2575; Ranola JMO et al. Fam Cancer, 2019 01;18:67-73; Ambry internal data). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Invitae | RCV000229520 | SCV000285091 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2024-01-12 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu625*) in the PMS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PMS2 are known to be pathogenic (PMID: 21376568, 24362816). This variant is present in population databases (rs786203073, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with colorectal cancer (PMID: 25856668, 26895986). ClinVar contains an entry for this variant (Variation ID: 186596). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV000413904 | SCV000490732 | pathogenic | not provided | 2023-03-03 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; This variant is associated with the following publications: (PMID: 26895986, 25856668, 27978560, 28514183, 30787465, 31447099, 32719484, 29345684, 30019097) |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000413904 | SCV000601831 | pathogenic | not provided | 2021-01-27 | criteria provided, single submitter | clinical testing | This nonsense variant causes the premature termination of PMS2 protein synthesis. It has been reported in individuals affected with colorectal cancer in the published literature (PMID: 26895986 (2016), 27978560 (2016)). Therefore, the variant is classified as pathogenic. |
Color Diagnostics, |
RCV000166215 | SCV000691048 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-06-11 | criteria provided, single submitter | clinical testing | This variant deletes 1 nucleotide in exon 11 of the PMS2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with colorectal cancer (PMID: 25856668, 26895986). This variant has been identified in 1/251448 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of PMS2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |
Laboratory for Molecular Medicine, |
RCV000603093 | SCV000713114 | pathogenic | Lynch syndrome | 2017-06-12 | criteria provided, single submitter | clinical testing | The p.Leu625X variant in PMS2 has been reported in at least 1 individual with a Lynch syndrome-associated cancer (Rosty 2016, Goodenberger 2016) and has also be en reported in ClinVar (Variation ID 186596). It was also identified in 1/111710 of European chromosomes by the Genome Aggregation Database (gnomAD; http://gnom ad.broadinstitute.org). This nonsense variant is a result of a deletion of 1 bas e at position 1874, which creates a premature termination codon at amino acid po sition 625. This alteration is then predicted to lead to a truncated or absent p rotein. Heterozygous loss of function of function of the PMS2 gene is an establ ished disease mechanism in Lynch syndrome. In summary, this variant meets criter ia to be classified as pathogenic for Lynch syndrome in an autosomal dominant ma nner based upon its absence from controls and predicted impact to the protein an d low frequency in controls. |
ARUP Laboratories, |
RCV000413904 | SCV000885995 | pathogenic | not provided | 2018-02-13 | criteria provided, single submitter | clinical testing | The PMS2 c.1874delT; p.Leu625Ter variant (rs786203073) has been reported in individuals with colorectal cancer (Goodenberger 2016, Rosty 2016). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 186596) and is seen in the general population at a low overall frequency of 0.0004% (1/246252 alleles) in the Genome Aggregation Database. This variant induces an early termination codon and is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on the above information, this variant is considered pathogenic. References: Goodenberger M et al. PMS2 monoallelic mutation carriers: the known unknown. Genet Med. 2016 Jan; 18(1): 13–19. Rosty C et al. Germline mutations in PMS2 and MLH1 in individuals with solitary loss of PMS2 expression in colorectal carcinomas from the Colon Cancer Family Registry Cohort. BMJ Open. 2016 Feb 19;6(2):e010293. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001797652 | SCV000920042 | pathogenic | Hereditary nonpolyposis colon cancer | 2021-11-23 | criteria provided, single submitter | clinical testing | Variant summary: PMS2 c.1874delT (p.Leu625X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-06 in 251448 control chromosomes (gnomAD). The c.1874delT variant has been reported in the literature in multiple individuals affected with Lynch Syndrome, though one 66 year old individual carrying the variant was unaffected (Goodenberger_2016), suggesting the possibility of reduced penetrance or later onset. However, these data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Myriad Genetics, |
RCV003454412 | SCV004187686 | pathogenic | Lynch syndrome 4 | 2023-09-21 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
Baylor Genetics | RCV003454412 | SCV004207872 | pathogenic | Lynch syndrome 4 | 2022-12-14 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000413904 | SCV004226928 | pathogenic | not provided | 2022-02-23 | criteria provided, single submitter | clinical testing | PP4, PM2, PVS1 |